<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> is a cornerstone of oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Recent joint American and European guidelines recommend instituting <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy along with lifestyle modification at the time type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) is diagnosed </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> acts to reduce hepatic gluconeogenesis and improve <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, and it may exert protective effects on pancreatic islet cells </plain></SENT>
<SENT sid="3" pm="."><plain>Although <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy produces substantial reductions in HbA1c, it does not produce body <z:mp ids='MP_0005456'>weight gain</z:mp>, is not associated with substantial risk for <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and has neutral to positive effects on <z:chebi fb="23" ids="18059">lipids</z:chebi> and blood pressure </plain></SENT>
<SENT sid="4" pm="."><plain>The major adverse events associated with <z:chebi fb="0" ids="6801">metformin</z:chebi> are gastrointestinal </plain></SENT>
<SENT sid="5" pm="."><plain>T2DM progresses even with initially effective monotherapy, and most patients will therefore receive combination therapy </plain></SENT>
<SENT sid="6" pm="."><plain>When selecting agents to coadminister with <z:chebi fb="0" ids="6801">metformin</z:chebi>, a physician must consider efficacy in glycaemic control, safety, tolerability and any effects that may compromise overall efficacy (e.g. effects on body weight, <z:chebi fb="23" ids="18059">lipids</z:chebi> or blood pressure) </plain></SENT>
<SENT sid="7" pm="."><plain>In this regard, incretin-based therapies have characteristics that make them particularly suitable for add-on therapy with <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
</text></document>